Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-01-24 DOI:10.1002/cam4.70369

Geoffrey Liu, Shi Feng Nyaw, Tony S. K. Mok, Hubert Curcio, Alexis B. Cortot, Tsz Yeung Kam, Renaud Descourt, Yin Kwan Chik, Parneet Cheema, James M. Gwinnutt, Eric N. Churchill, Justin Nyborn, Eileen Curran, Alexandra Savell, Yu Yin, Katie Chong, Yuka Tanaka-Chambers, Julian Kretz, Jacques Cadranel

{"title":"Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study","authors":"Geoffrey Liu, Shi Feng Nyaw, Tony S. K. Mok, Hubert Curcio, Alexis B. Cortot, Tsz Yeung Kam, Renaud Descourt, Yin Kwan Chik, Parneet Cheema, James M. Gwinnutt, Eric N. Churchill, Justin Nyborn, Eileen Curran, Alexandra Savell, Yu Yin, Katie Chong, Yuka Tanaka-Chambers, Julian Kretz, Jacques Cadranel","doi":"10.1002/cam4.70369","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Real-world data regarding patients with non-small cell lung cancer (NSCLC) with <i>EGFR</i> exon 20 insertion (<i>ex20ins</i>) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423). The inclusion criteria were: ≥ 18 years old; diagnosis of stage IIIB-IV NSCLC with <i>EGFR ex20ins</i> between January 1, 2017 and November 30, 2021; received mobocertinib. Data on demographics, clinical parameters, treatment patterns, mobocertinib exposure, real-world outcomes, and adverse events (AEs) were collected. Results are also reported by Asian/Non-Asian races.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall, 105 patients were enrolled (median [IQR] age at initial diagnosis: 64.0 years [56, 71]; women: 62.9%). The most common first-line of therapy (LoT) was chemotherapy; the most common second LoT was EGFR tyrosine kinase inhibitors. Most patients received mobocertinib during LoT two and three (74.3%); the maximum dose was 160 mg/day for 67.6% of the cohort (mean [SD] daily dose: 130.6 mg [36.68]). The median real-world progression-free survival (PFS) on mobocertinib was 4.76 months (95% CI: 3.98, 6.21). The overall response rate and disease control rate were 20.0% and 48.6%, respectively (median duration of response: 8.34 months [95% CI: 3.61, 9.49]). The median overall survival (OS) was 26.28 months (95% CI: 20.21, 36.44). Asian patients had numerically superior PFS and OS compared with non-Asian patients. Regarding safety analysis, 73 patients (69.5%) experienced any AE. The most common AE was diarrhea (any grade) (52 patients; 49.5%).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These data illustrate the real-world effectiveness of mobocertinib.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 3","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761427/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70369","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.

Methods

A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423). The inclusion criteria were: ≥ 18 years old; diagnosis of stage IIIB-IV NSCLC with EGFR ex20ins between January 1, 2017 and November 30, 2021; received mobocertinib. Data on demographics, clinical parameters, treatment patterns, mobocertinib exposure, real-world outcomes, and adverse events (AEs) were collected. Results are also reported by Asian/Non-Asian races.

Results

Overall, 105 patients were enrolled (median [IQR] age at initial diagnosis: 64.0 years [56, 71]; women: 62.9%). The most common first-line of therapy (LoT) was chemotherapy; the most common second LoT was EGFR tyrosine kinase inhibitors. Most patients received mobocertinib during LoT two and three (74.3%); the maximum dose was 160 mg/day for 67.6% of the cohort (mean [SD] daily dose: 130.6 mg [36.68]). The median real-world progression-free survival (PFS) on mobocertinib was 4.76 months (95% CI: 3.98, 6.21). The overall response rate and disease control rate were 20.0% and 48.6%, respectively (median duration of response: 8.34 months [95% CI: 3.61, 9.49]). The median overall survival (OS) was 26.28 months (95% CI: 20.21, 36.44). Asian patients had numerically superior PFS and OS compared with non-Asian patients. Regarding safety analysis, 73 patients (69.5%) experienced any AE. The most common AE was diarrhea (any grade) (52 patients; 49.5%).

Conclusions

These data illustrate the real-world effectiveness of mobocertinib.

Abstract Image

查看原文本刊更多论文

接受Mobocertinib治疗EGFR外显子20插入突变的非小细胞肺癌患者的治疗模式和实际结果：EXTRACT研究

背景：关于EGFR外显子20插入（ex20ins）突变的非小细胞肺癌（NSCLC）患者接受mobocertinib治疗的真实数据有限。本研究描述了这些患者的特征和结果。方法：在三个国家（加拿大、法国和香港）进行图表回顾，从符合条件的患者（NCT05207423）中提取数据。纳入标准为：年龄≥18岁；2017年1月1日至2021年11月30日期间诊断为EGFR ex20ins的IIIB-IV期NSCLC；收到mobocertinib。收集了人口统计学、临床参数、治疗模式、莫博西替尼暴露、实际结果和不良事件（ae）的数据。亚洲/非亚洲种族也报告了结果。结果：共纳入105例患者(初诊时中位[IQR]年龄：64.0岁[56,71]；女性:62.9%)。最常见的一线治疗（LoT）是化疗；最常见的第二种LoT是EGFR酪氨酸激酶抑制剂。大多数患者在LoT 2和LoT 3期间接受了mobocertinib (74.3%)；67.6%的队列患者最大剂量为160 mg/天（平均[SD]日剂量：130.6 mg[36.68]）。mobocertinib的中位真实无进展生存期（PFS）为4.76个月（95% CI: 3.98, 6.21）。总有效率和疾病控制率分别为20.0%和48.6%（中位缓解持续时间：8.34个月[95% CI: 3.61, 9.49]）。中位总生存期（OS）为26.28个月（95% CI: 20.21, 36.44）。与非亚洲患者相比，亚洲患者的PFS和OS在数字上更优越。安全性分析方面，73例患者（69.5%）出现AE。最常见的AE是腹泻（任何级别）(52例；49.5%)。结论：这些数据说明了mobocertinib在现实世界中的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.